OOIR: Observatory of International Research

Papers

(The H4-Index of Translational Oncology is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
Elacestrant in metastatic breast cancer: Is the “standard of care” meeting standard requirements?	1332
The other side of the coin: dissecting molecular mechanisms behind hereditary breast cancer in search of therapeutic opportunities	109
Enhancing chemotherapy response prediction via matched colorectal tumor-organoid gene expression analysis and network-based biomarker selection	86
A practical distribution pattern of α-SMA-positive carcinoma associated fibroblasts indicates poor prognosis of patients with pancreatic ductal adenocarcinoma	79
Role of 3-mercaptopyruvate sulfurtransferase in cancer: Molecular mechanisms and therapeutic perspectives	72
Evaluation of S100A8/A9 and neutrophils as prognostic markers in metastatic melanoma patients under immune-checkpoint inhibition	69
CDK4/6 inhibitors promote PARP1 degradation and synergize with PARP inhibitors in non-small cell lung cancer	67
AFP shields hepatocellular carcinoma from macrophage phagocytosis by regulating HuR-mediated CD47 translocation in cellular membrane	67
Hypericin mediated photodynamic therapy induces ferroptosis via inhibiting the AKT/mTORC1/GPX4 axis in cholangiocarcinoma	56
Clinical characteristics of EGFR-ctDNA shedders in EGFR-mutant NSCLC patients	56
MAGI2-AS3 hypermethylated in promoter region promotes migration and invasion of head and neck squamous cell carcinoma via miRNA-31-5p/AR axis	46
Comment on: AI-supported modified risk staging for multiple myeloma cancer useful in real-world scenario	45
Hypoxia induced cell dormancy of salivary adenoid cystic carcinoma through miR-922/DEC2 axis	42
Which evaluation criteria of the short-term efficacy can better reflect the long-term outcomes for patients with nasopharyngeal carcinoma?	42
Identification of IMPA2 as the hub gene associated with colorectal cancer and liver metastasis by integrated bioinformatics analysis	41
Analysis of patient reported outcomes included in the registrational clinical trials of nivolumab for advanced non-small cell lung cancer	41
ALYREF associated with immune infiltration is a prognostic biomarker in hepatocellular carcinoma	39
Preoperative neutrophil-to-lymphocyte ratio (preNLR) for the assessment of tumor characteristics in lung adenocarcinoma patients with brain metastasis	38
Synergistic effect of sodium butyrate and oxaliplatin on colorectal cancer	37
Lung cancer and oncolytic virotherapy——enemy's enemy	37
Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitors	37
Genomic identification of sarcoma radiosensitivity and the clinical implications for radiation dose personalization	36
SnoRNA U50A mediates everolimus resistance in breast cancer through mTOR downregulation	35
Evolutionary dynamics of cancer multidrug resistance in response to olaparib and photodynamic therapy	34
FUBP1 in human cancer: Characteristics, functions, and potential applications	34

The STAT3 inhibitor GPB730 enhances the sensitivity to enzalutamide in prostate cancer cells	33
Neoadjuvant checkpoint inhibition in non-small cell lung cancer: Is earlier unquestionably better than later?	32
Single-treatment tumor ablation with photodynamic liposomal irinotecan sucrosulfate	31
Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancers	31
BX-795 inhibits neuroblastoma growth and enhances sensitivity towards chemotherapy	31
Liquid Biopsies: Emerging role and clinical applications in solid tumours	31